Research programme: reproductive health and immunology therapeutics - Santhera/Serono
Alternative Names: Reproductive health and immunology therapeutics research programme - Santhera/SeronoLatest Information Update: 12 Mar 2008
At a glance
- Originator Merck Serono; Santhera Pharmaceuticals
- Developer Santhera Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Infertility
Most Recent Events
- 12 Mar 2008 Discontinued - Preclinical for Immunological disorders in Germany (unspecified route)
- 12 Mar 2008 Discontinued - Preclinical for Infertility in Germany (unspecified route)
- 05 Jan 2007 Serono has been acquired by Merck KGaA